NCT04648813View on ClinicalTrials.gov

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

April 20, 2021

Study Completion Date

April 20, 2021

Conditions
Allergic Asthma
Interventions
DRUG

tiotropium bromide monohydrate (Spiriva Respimat)

administered daily, 2 inhalations/5mcg per dose for a total of 8 doses

DRUG

matching placebo

administered daily, 2 inhalations per dose for a total of 8 doses

Trial Locations (1)

S7N 0W8

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall, Saskatoon

All Listed Sponsors
lead

University of Saskatchewan

OTHER

NCT04648813 - Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses | Biotech Hunter | Biotech Hunter